

Case Study: Mankind Pharma's Acquisition of Bharat Serum Vaccines

– Chandan Sharma*

Assistant Professor, Delhi School of Management, Delhi Technological University, Delhi, India
✉ chandansharma.phd@gmail.com  <https://orcid.org/0000-0003-4725-1715>

– Deep Shree

Assistant Professor Delhi School of Management, Delhi Technological University
✉ deep29shree@gmail.com  <https://orcid.org/0000-0003-2173-7936>



ARTICLE HISTORY

Paper Nomenclature: Case Based Study (CBS)
Paper Code: GJEISV16I3JS2024CBS1
Submission at Portal (www.gjeis.com): 03-July-2024
Manuscript Acknowledged: 10-July-2024
Originality Check: 26-July-2024
Originality Test (Plag) Ratio (Turnitin): 07%
Author Revert with Rectified Copy: 29-Jul-2024
Peer Reviewers Comment (Open): 30-Jul-2024
Single Blind Reviewers Explanation: 12-Aug-2024
Double Blind Reviewers Interpretation: 19-Aug-2024
Triple Blind Reviewers Annotations: 28-Aug-2024
Author Update (w.r.t. correction, suggestion & observation): 03-Sept-2024
Camera-Ready-Copy: 12-Sept-2024
Editorial Board Excerpt & Citation: 22-Sept-2024
Published Online First: 30-Sept-2024

ABSTRACT

Purpose: This case study investigates Mankind Pharma's acquisition of Bharat Serum Vaccines (BSV), aiming to understand the strategic motivations, financial implications, and operational synergies involved in this significant merger within the pharmaceutical sector.

Design/Methodology/Approach: The study employs a qualitative approach, analyzing financial data, market trends, and competitive positioning to assess the acquisition's potential impact. It synthesizes insights from industry reports and financial projections to provide a comprehensive evaluation of the deal's implications for Mankind Pharma.


Findings: The acquisition is poised to enhance Mankind's product offerings and R&D capabilities, particularly in women's health and fertility treatments. Financial projections suggest that BSV will contribute significantly to Mankind's EBITDA growth, with an expected sales CAGR of 20% over the next few years. The deal is anticipated to be EPS-accretive from the second year post-acquisition, reflecting a favorable valuation based on BSV's growth potential.

Originality/Value: This case study contributes to the understanding of strategic acquisitions in the pharmaceutical industry, particularly within emerging markets. It provides valuable insights into how Mankind Pharma can leverage BSV's established market presence and innovative product pipeline to drive sustainable growth.

Paper Type: Case Based Study

KEYWORDS: Pharmaceutical Acquisition | Mergers & Acquisitions | Vaccine Market Expansion | Strategic Business Growth

*Corresponding Author (Chandan)

- 
- Present Volume & Issue (Cycle): Volume 16 | Issue-3 | Jul-Sept 2024
 - International Standard Serial Number:
Online ISSN: 0975-1432 | Print ISSN: 0975-153X
 - DOI (Crossref, USA) <https://doi.org/10.18311/gjeis/2024>
 - Bibliographic database: OCLC Number (WorldCat): 988732114
 - Impact Factor: 3.57 (2019-2020) & 1.0 (2020-2021) [CiteFactor]
 - Editor-in-Chief: Dr. Subodh Kesharwani
 - Frequency: Quarterly

- Published Since: 2009
- Research database: EBSCO <https://www.ebsco.com>
- Review Pedagogy: Single Blind Review/ Double Blind Review/ Triple Blind Review/ Open Review
- Copyright: ©2024 GJEIS and it's heirs
- Publishers: Scholastic Seed Inc. and KARAM Society
- Place: New Delhi, India.
- Repository (figshare): 704442/13

GJEIS is an Open access journal which access article under the Creative Commons. This CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0>) promotes access and re-use of scientific and scholarly research and publishing.

Introduction

Mankind Pharma has established itself as a prominent player in the Indian pharmaceutical industry since its inception in 1991. With a diverse product portfolio and a strong market presence, Mankind has sought opportunities for growth through innovation and strategic acquisitions. The acquisition of Bharat Serum Vaccines represents a defining moment in Mankind's journey, positioning it to capitalize on emerging trends in specialty pharmaceuticals.

Background of Mankind Pharma

Founded in 1991, Mankind Pharma has grown rapidly to become one of India's leading pharma sector companies. The company focuses on supplying high-quality medicines across various therapeutic areas, including cardiology, gynecology, urology, and anti-infectives. Mankind Pharma has built a strong reputation for its commitment to R&D, enabling it to launch over several brands that cater to diverse healthcare needs.

Mankind's business model is characterized by a robust distribution network and a strong emphasis on marketing. The company has established relationships with healthcare professionals and institutions, allowing it to effectively promote its products. As of FY24, Mankind reported total sales of INR 103.3 billion and an EBITDA of INR 25.4 billion.

Overview of Bharat Serum Vaccines

Bharat Serum Vaccines was founded in 1971 and specializes in producing vaccines and biologics with a focus on women's health, fertility treatments, and critical care. BSV has developed a robust product pipeline and has established itself as a leader in recombinant technology. The company's commitment to innovation has led to significant growth, with a reported sales CAGR of 21% from FY21 to FY24. Most of the leading product in the company portfolio enjoy limited competition in their segment in the domestic market and thus have witnessed double digit growth over FY21-24 (Mankind Pharma Limited, 2024a).

BSV's product offerings include recombinant Anti-D immunoglobulin used for treating Rhesus disease, fertility drugs such as r-FSH and r-HCG, and critical care products like anti-thymocyte globulin. With two manufacturing facilities located in Ambernath (India) and Germany, BSV is well-equipped to meet both domestic and international demand (Mankind Pharma, 2024a).

Strategic Rationale for the Acquisition

The acquisition of BSV aligns with Mankind Pharma's strategic goals for several reasons:

1. Expansion of Product Portfolio

By acquiring BSV, Mankind Pharma gains access to a diverse range of specialized products, particularly in women's health and fertility treatments. This includes complex biologics and high-entry barrier products that complement Mankind's existing offerings. The integration of BSV's portfolio is expected to enhance Mankind's market position significantly (Mankind Pharma, 2024b).

2. Enhanced Research and Development Capabilities

BSV's advanced R&D capabilities are crucial for Mankind as it seeks to innovate and expand its product offerings. BSV is recognized globally for its recombinant Anti-D immunoglobulin, which treats Rhesus disease—a condition affecting pregnant women. This expertise will bolster Mankind's capabilities in developing new therapies.

3. Strengthening Market Position

The acquisition allows Mankind to leverage BSV's established market presence and distribution channels. With BSV generating approximately 46% of its revenue from international markets, this acquisition enhances Mankind's global reach and strengthens its competitive position against both domestic players and multinational corporations.

4. Access to High-Entry Barrier Markets

BSV operates within high-entry barrier segments such as complex biologics and specialty pharmaceuticals. The acquisition enables Mankind to penetrate these lucrative markets more effectively while benefiting from BSV's existing relationships with healthcare providers and institutions.

Financial Implications

The financial structure of the acquisition involves raising INR 40 billion through internal accruals and remaining primarily through debt. Mankind anticipates that cash flow generated from its existing operations will facilitate debt repayment post-acquisition.

Pro Forma Financial Projections

Based on estimates, BSV is expected to contribute significantly to Mankind's EBITDA growth:

FY25: Projected EBITDA from BSV is expected to cross INR 6 bn (FY24 EBITDA – INR 4.89 bn).

Sales Growth: Expected sales CAGR of around 20% over FY25-27 (FY21-24: Sales CAGR – 21%).

EBITDA Margin: Further improvement in EBITDA margin from 28% in FY24



Valuation Metrics

The deal valuation implies an EV/EBITDA multiple of approximately 28x based on FY24 figures, which is considered fair given the growth potential of BSV's business model. Analysts project that this acquisition will be EPS-accretive from FY26 onwards (Mankind Pharma Limited, 2024b).

Operational Synergies

Mankind expects several operational synergies from the acquisition:

1. Manufacturing Efficiency

BSV operates two advanced manufacturing facilities with capabilities in producing injectables and active pharmaceutical ingredients (APIs). This enhances Mankind's manufacturing capacity and efficiency, allowing for streamlined operations.

2. Sales Growth Potential

Integrating BSV's sales force into Mankind's operations is projected to improve market penetration across both companies' product lines. With BSV sales force of 260+ staff across 15 countries, the potential for increased sales is substantial.

3. Cost Synergies

The consolidation of operations is expected to lead to cost efficiencies through improved productivity and reduced operational redundancies.

4. Leveraging Distribution Networks

Mankind can leverage BSV's established distribution networks both domestically and internationally, enhancing its ability to reach new markets effectively.

Market Outlook

The global market for fertility drugs is projected to grow to USD 9.9 bn by 2027 (FY22 : USD 6.2 bn). By acquiring BSV, Mankind positions itself to capture a larger share of this growing segment, particularly given the low penetration rates in India and emerging markets.

Competitive Landscape

Mankind faces competition from both domestic players and multinational corporations in the specialty pharmaceuticals sector. However, BSV's established brand presence and innovative product offerings provide a competitive edge that can be leveraged post-acquisition.

Regulatory Environment

Navigating regulatory landscapes will be crucial for successful market expansion post-acquisition. BSV has experience in dealing with complex regulatory requirements across various international markets, which will benefit Mankind as it seeks to expand its global footprint.

Challenges Ahead

While the acquisition presents numerous opportunities, several challenges must be addressed:

1. Integration Risks

Effective integration of BSV into Mankind's operations is critical for realizing synergies and achieving projected financial targets. Cultural differences between the two organizations may pose challenges during this process.

2. Market Dynamics

The pharmaceutical industry is subject to rapid changes due to technological advancements and evolving consumer preferences. Staying ahead of these trends will be essential for maintaining competitive advantage.

3. Debt Management

With significant debt incurred for the acquisition, managing financial health while ensuring sustainable growth will be paramount for Mankind.

Conclusion

Mankind Pharma's acquisition of Bharat Serum Vaccines represents a strategic initiative aimed at diversifying its product portfolio and enhancing its capabilities in specialty pharmaceuticals. With robust financial planning and operational synergies anticipated from this deal, Mankind is well-positioned for sustainable growth in a competitive landscape.

Future Directions

As Mankind integrates BSV into its operations, it must focus on effective change management strategies that promote collaboration between teams while maintaining operational efficiency. Continuous investment in R&D will also be essential for driving innovation within the newly expanded portfolio. This case study provides an overview of Mankind Pharma's strategic acquisition of Bharat Serum Vaccines while highlighting key elements such as financial implications, operational synergies, market outlooks, challenges ahead, and future directions post-acquisition. The successful execution of this acquisition could significantly enhance Mankind's position within the pharmaceutical industry while providing valuable insights into best practices for future mergers and acquisitions within this sector.

References

- Mankind Pharma. (2024a). *Investor Presentation*.
- Mankind Pharma. (2024b). *Investor Presentation - Key credit Highlights*. https://www.mankindpharma.com/wp-content/uploads/2024/12/20240902_intimation_se_sd-1725295027.pdf
- Mankind Pharma Limited. (2024a). *Financials*. <https://www.mankindpharma.com/investors-relations/financials/>
- Mankind Pharma Limited. (2024b). *Mankind Pharma Limited Conference Call*. https://www.mankindpharma.com/wp-content/uploads/2024/12/mankindpharma_bsv_acquisition_call_transcript-1722573520.pdf

GJEIS Prevent Plagiarism in Publication

The Editorial Board had used the Turnitin is an Internet-based similarity detection service run by the American company Turnitin, LLC, a subsidiary of Advance Publications which is a fully-automatic machine learning text- recognition system made for detecting, preventing and handling plagiarism and trusted by thousands of institutions across worldwide. Turnitin is an award-winning software that helps detect and prevent plagiarism regardless of language. Combining text- matching with writing-style analysis to promote academic integrity and prevent plagiarism, Ouriginal is simple, reliable and easy to use. Ouriginal was acquired by Turnitin in 2021. As part of a larger global organization GJEIS and Turnitin better equipped to anticipate the foster an environment of academic integrity for educators and students around the globe. Ouriginal is GDPR compliant with privacy by design and an uptime of 99.9% and have trust to be the partner in academic integrity (<https://www.ouriginal.com/>) tool to check the originality and further affixed the similarity index which is {07%} in this case (See below Annexure 16.3.5). Thus, the reviewers and editors are of view to find it suitable to publish in this Volume-16, Issue-3, Jul-Sept 2024.

Annexure 16.3.5

Submission Date	Submission	Word Count	Character Count
26-July-2024	Turnitin	1294	8429

Analyzed Document	Submitter email	Submitted by	Similarity
3.1 CBS1_Chandan_GJEIS Jul to Sept 2024.docx	chandansharma.phd@gmail.com	Chandan Sharma	07%



1	coherentmarketinsights.com Internet	2%	5	Indian School of Business on 2024-09-26 Submitted works	<1%
2	Saito University College on 2024-07-26 Submitted works	1%	6	La Trobe University on 2022-08-18 Submitted works	<1%
3	Johnson High School on 2023-11-11 Submitted works	<1%	7	Yonsei University on 2024-03-31 Submitted works	<1%
4	mediummultimedia.com Internet	<1%			

Reviewers Memorandum



Reviewer's Comment 1: The article effectively highlights the key elements of Mankind Pharma's strategic acquisition of Bharat Serum Vaccines, such as the strategic rationale for the acquisition, market outlooks, financial implications, operational synergies, challenges ahead, and future directions post-merger. The article makes it clear how acquisition of Bharat Serum Vaccines (BSV) by Mankind Pharma is strategically beneficial and significant.

Reviewer's Comment 2: While the article covers various aspects of post-acquisition of Bharat Serum Vaccines by Mankind Pharma. The article is very well structured and clearly presents the rationale of acquisition, the financial implications of post-acquisition, and focused on operational synergies. However, some sections could be further provided in a detailed manner for clarity. For instance, the discussion on challenges ahead of post-acquisition may be discussed in detail, and also possible solutions may be recommended, which will help the company managers in providing direction to tackle these challenges posed by merger.

Reviewer's Comment 3: The article is well-structured and easy to follow. The article showed how this merger helps in expansion of product portfolio, enhancing R&D capabilities, strengthening market position, and accessing the high-entry barrier markets. Also highlighted post-acquisition risks include integration risks, market dynamics, and debt management. However, the facts and figures may be supported by diagrams to aid understanding. Overall, the article is well written and easy to read.

Editorial Excerpt



The article has 7% of plagiarism, which is the accepted percentage as per the norms and standards of the journal for publication. As per the editorial board's observations and blind reviewers' remarks the paper had some minor revisions, which were communicated on a timely basis to the authors (Chandan and Deep Shree), and accordingly, all the corrections had been incorporated as and when directed and required to do so. The comments related to this manuscript are noticeably related to the theme "**Case Study: Mankind Pharma's Acquisition of Bharat Serum Vaccines**" both subject-wise and research-wise. The article presents strategic rationale for the acquisition, financial implications of post-acquisition, operational synergies, and potential challenges after merger. The paper is presented in easy-to-understand language. However, to further enrich the paper, it would be beneficial to further elaborate on some sections. After comprehensive reviews and the editorial board's remarks, the manuscript has been categorized and decided to publish under the "**Case Based Study**" category.

Acknowledgement



The acknowledgement section is an essential part of all academic research papers. It provides appropriate recognition to all contributors for their hard work and effort taken while writing a paper. The data presented and analyzed in this paper by the author (Chandan and Deep Shree) were collected first handily and wherever it has been taken the proper acknowledgment and endorsement depicts. The author is highly indebted to others who facilitated accomplishing the research. Last but not least, endorse all reviewers and editors of GJEIS in publishing in the present issue.

Disclaimer



All views expressed in this paper are my/our own. Some of the content is taken from open-source websites & some are copyright free for the purpose of disseminating knowledge. Those some we/I had mentioned above in the references section and acknowledged/cited as when and where required. The author/s have cited their joint own work mostly, and tables/data from other referenced sources in this particular paper with the narrative & endorsement have been presented within quotes and reference at the bottom of the article accordingly & appropriately. Finally, some of the contents are taken or overlapped from open-source websites for knowledge purposes. Those some of i/we had mentioned above in the references section. On the other hand, opinions expressed in this paper are those of the author and do not reflect the views of the GJEIS. The authors have made every effort to ensure that the information in this paper is correct, any remaining errors and deficiencies are solely their responsibility.

Citation

Chandan Sharma and Deep Shree
"Case Study: Mankind Pharma's
Acquisition of Bharat Serum Vaccines"
Volume-16, Issue-3, Jul-Sept 2024. (www.gjeis.com)

<https://doi.org/10.18311/gjeis/2024>
Volume-16, Issue-3, Jul-Sept 2024

Online iISSN : 0975-1432, Print iISSN : 0975-153X
Frequency : Quarterly, Published Since : 2009

Google Citations: Since 2009
H-Index = 96
i10-Index: 964

Source: <https://scholar.google.co.in/citations?user=S47TtNkAAAAJ&hl=en>



Conflict of Interest: Author of a Paper
had no conflict neither financially nor academically.